These authors have contributed equally to this work
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
In the published article, there was an error in
Basic characteristics of included studies.
| Source | Country | Type of patients | Duration | Intervention | Control |
Outcomes | Adverse event | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Intervention method (Dose) | Population |
Mean age | method (Dose) | Population |
Mean age | ||||||
|
|
Italy | CRSwNP | 3 months | Mometasone furoate nasal spray (200μg, once daily) |
40 | 56.9 ± 5.6α | Mometasone furoate nasal spray (200μg, once daily) |
40 | 56.8 ± 4.4α | Nasal Congestion, Rhinorrhea, Nasal Endoscopy Scoring, Quality of life | No adverse reactions |
|
|
Italy | CRS | 3 months | SH plus saline solution (9mg, twice/day) | 21 (13) | 44 (30–63) β | Saline solution (5mL, twice/day) | 18 (10) | 38 (34–58) β | Rhinitis | No adverse reactions |
|
|
Italy | CRSwNP | 3 months | SH plus saline (9mg, twice daily) | 20 (12) | 38.75 ± 13.08α | Saline (5mL, twice daily) | 20 (11) | 38.6 ± 13.06α | Rhinitis, Mucociliary clearance, Nasal Endoscopy Scoring, Rhinomanometry | Headache, Throat irritation, Upper respiratory infection, Epistaxis, Nasal burning |
| Mometasone furoate nasal sprays (200μg, twice daily) |
20 (12) | 38.85 ± 13.31α | Mometasone furoate nasal sprays (200μg, twice daily) | 20 (10) | 38.4 ± 12.7α | ||||||
|
|
Italy | ARS | 30 days | Levofloxacin (500mg, 10days) |
24 (12) | 44 (38–50) * | Levofloxacin (500mg, 10days) |
24 (14) | 43 (35–55) * | Nasal Congestion, Rhinorrhea, Eosinophils, Neutrophils, mucociliary clearance, Hyposmia | Not reported |
|
|
Turkey | AR in children | 28 days | Nasal fluticasone furoate (1 puff/nostril, once daily) |
26 (18) | 8.38 ± 1.89α | Nasal fluticasone furoate (1 puff/nostril, once daily) |
24 (12) | 8.5 ± 1.31α | Nasal Congestion, Rhinorrhea, Rhinitis, Itching, Sneezing, Eosinophils, Quality of life, Rhinomanometry | Nasal irritation and burning sensation |
| Nasal fluticasone furoate (1 puff/nostril, once daily) |
26 (18) | 8.38 ± 1.89α | Nasal fluticasone furoate (1 puff/nostril, once daily) | 26 (18) | 8.69 ± 1.7α | ||||||
|
|
Italy | Pregnancy Rhinitis | until delivery | SH (9mg/vial; 2 vials daily for 14 days, followed by 15 days of interruption of therapy; subsequently 1 vial daily for 10 and 15 days of interruption of therapy; lastly 1 vial daily for 10 days) | 28 | 31.6 ± 5.5α | Not receive any treatment | 27 | 28.1 ± 4.8α | Rhinorrhea | No adverse reactions |
|
|
Italy | AR and vasomotor rhinitis | 30 days | Mometasone furoate nasal spray (50μg/spray, 2 sprays/nostril once daily) |
39 (23) | 21–63β | Mometasone furoate nasal spray (50μg/spray, 2 sprays/nostril once daily) |
39 (21) | 22–61β | Nasal Congestion, Rhinorrhea, Eosinophils, Neutrophils | Not reported |
|
|
Italy | AR, NAR, and MR | 4 weeks | intranasal mometasone furoate (1 puff/nostril, twice daily) |
48 | Not reported | intranasal mometasone furoate (1 puff/nostril, twice daily) |
41 | Not reported | Nasal Congestion, Rhinorrhea, Itching, Sneezing, Hyposmia | No adverse reactions |
|
|
Turkey | AR | 30 days | Triamcinolone acetonide sprays (256 μg/day, 1 puff/nostril, once daily) |
32 (14) | 34 (18–68) β | Triamcinolone acetonide sprays (256 μg daily, 1 puff/nostril, once daily) |
33 (13) | 36 (18–61) β | Mucociliary clearance | No adverse reactions |
|
|
Italy | CRSsNP | 30 days | SH (5mg, twice daily) | 15 | Not reported | Isotonic saline solution (5mg, twice daily) | 15 | Not reported | Nasal Congestion, Rhinorrhea, Eosinophils, Neutrophils, Nasal Endoscopy Scoring, Quality of life, Hyposmia | No adverse reactions |
|
|
Germany | Dry nose symptoms | 4 weeks | SH (1–2 sprays/nostril)/Hyaluronic acid plus dexpanthenol (1–2 sprays/nostril) | 79 (41)/ |
54.15 ± 17.03α/50.60 ± 18.98α | Isotonic saline (1–2 sprays/nostril) | 80 (31) |
50.27 ± 19.7α | Nasal Congestion, Rhinorrhea, Rhinitis, Itching, Sneezing, Hyposmia | Cephalgia |
CRS, chronic rhinosinusitis; CRSwNP, chronic rhinosinusitis with nasal polyposis; CRSsNP, chronic rhinosinusitis without nasal polyposis; ARS, acute rhinosinusitis; NAR, nonallergic rhinitis; MR: mixed rhinitis; SH, sodium hyaluronate; α, Mean age ± SD; β, Mean age (range); *, median (IQR).
In the published article, there was an error. The authors found that the occurrence of cephalgia was possibly related the use of nasal spray (Thieme et al., 2020), however, this was omitted in the meta-analysis.
A correction has been made to
“These studies (Cassandro et al., 2015; Ercan et al., 2022) reporting adverse events included nasal burning, headaches, throat irritation, upper respiratory tract infections, epistaxis, and nasal irritation. One trial (Cassandro et al., 2015) reported no difference in the incidence of adverse events between the HA and control groups, and the other trial (Ercan et al., 2022) showed only mild adverse events in the control group.”
The corrected sentence appears below:
“These studies (Cassandro et al., 2015; Ercan et al., 2022) reported adverse events including nasal burning, headache, throat irritation, upper respiratory tract infection, epistaxis, and nasal irritation. One patient reported thrice about the occurrence of cephalgia in hyaluronic acid plus dexpanthenol group, rated as possibly related to the application of the nasal spray (Thieme et al., 2020). One trial (Cassandro et al., 2015) reported no difference in the incidence of adverse events between the HA and control groups, and the other trial (Ercan et al., 2022) showed only mild adverse events in the control group.”
In the published article, there was an error in
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.